C. Dilea

发表

First‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives

H Boxenbaum, H. Boxenbaum, C. Dilea, 1995, Journal of clinical pharmacology.

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma

T. Cloughesy, D. Reardon, J. Rich, 2011, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function

Y. Wong, C. Dilea, M. Marino, 2003, Journal of clinical pharmacology.

The Pharmacokinetics of Oral Isradipine in Normal Volunteers

R. Blouin, H. Schran, C. Dilea, 1988, Journal of clinical pharmacology.

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

P. Richardson, R. Perez, P. Sabbatini, 2014 .

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

B. Smith, P. Sabbatini, J. Altman, 2014 .

Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen

J. Baselga, C. Takimoto, F. Rojo, 2005 .

The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers

K. Lasseter, Kyle T. Matschke, J. Korth-Bradley, 2014, Clinical pharmacology in drug development.

Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers

S. Troy, R. Fruncillo, Patrick Martin, 1997 .

PHARMACOKINETICS OF ONCE-DAILY VENLAFAXINE EXTENDED RELEASE IN HEALTHY VOLUNTEERS

S. Troy, R. Fruncillo, Patrick Martin, 1997 .

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients

K. Aldape, W. Yung, M. Prados, 2012, Cancer Chemotherapy and Pharmacology.

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

J. Burke, J. Leonard, A. Krishnan, 2020 .

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.

J. Mestan, P. Manley, O. Yin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia.

J. Mestan, P. Manley, O. Yin, 2009 .

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).

F. Braiteh, R. Schilder, D. Uyar, 2021 .

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Patrick Schöffski, Alain C. Mita, Josep Tabernero, 2012, Clinical Cancer Research.

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

J. Burke, J. Leonard, A. Krishnan, 2019, Blood.

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

J. Baselga, C. Takimoto, J. Tabernero, 2012, Clinical Cancer Research.